Amaris first to offer two energy levels

Article

Amaris is the first refractive laser in the world to offer two separate energy levels for optimal corneal smoothing, according to an announcement from Schwind, the laser's manufacturer.

Amaris is the first refractive laser in the world to offer two separate energy levels for optimal corneal smoothing, according to an announcement made by Schwind, the laser's manufacturer.

The laser, which has a 500 Hz pulse frequency, includes a unique "Automatic Fluence Level Adjustment" feature, enabling the laser to switch between high and low levels of fluence to provide the most appropriate energy level for each cornea. Approximately 80% of the ablation is performed at high fluence; for the remaining 20% of the procedure, the laser automatically lowers the fluence value to whatever level is most appropriate. Dual fluence levels are also able to treat subjective refractions and higher order aberrations.

Schwind believes that this combination of high and low fluence values and pulse frequencies offers optimum results for patients, as well as increasing the lifetime of the equipment.

The images show ablation variations: please click on an image to enlarge.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.